Clinical Trial Update: A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation for Treatment of Stage IV Melanoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 trial of A-dmDT390-bisFv(UCHT1) fusion protein in combination with ionizing radiation for stage IV melanoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• A-dmDT390-bisFv(UCHT1) fusion protein

Snippet

Sponsor: Angimmune LLC | Conditions: Melanoma | Phase 1, Phase 2 | Status: TERMINATED